# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cramer recommends staying away from Canada Goose, even though it reported better-than-expected Q4 earnings.
- Reuters
More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment o...
Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $14...